What is Leerink Partnrs' Estimate for Zai Lab Q1 Earnings?

Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Zai Lab in a research note issued on Thursday, February 20th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share. Leerink Partnrs also issued estimates for Zai Lab's Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.15). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

Separately, Cantor Fitzgerald raised Zai Lab to a "strong-buy" rating in a report on Wednesday, February 5th.

Zai Lab Stock Down 2.0 %

ZLAB traded down $0.69 on Monday, reaching $34.38. The company's stock had a trading volume of 1,593,393 shares, compared to its average volume of 854,875. The stock has a 50 day moving average of $27.35 and a two-hundred day moving average of $25.63. The company has a market capitalization of $3.76 billion, a price-to-earnings ratio of -12.41 and a beta of 1.02. Zai Lab has a fifty-two week low of $13.48 and a fifty-two week high of $36.60.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.88% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Zai Lab in the 4th quarter valued at $29,000. Pictet Asset Management Holding SA acquired a new position in Zai Lab in the 4th quarter valued at $31,000. Barclays PLC increased its stake in Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after buying an additional 2,856 shares during the period. US Bancorp DE increased its stake in Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock valued at $154,000 after buying an additional 5,534 shares during the period. Finally, Jasper Ridge Partners L.P. acquired a new position in Zai Lab in the 4th quarter valued at $210,000. 41.65% of the stock is owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.